Early Phase 1 Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with breast cancer at Stage I, II, or III, with any hormonal receptor status
- Women aged 18 years or older
- People who are currently taking a type of hormone-blocking medication called an aromatase inhibitor (AI)
- People with a body mass index (BMI) of 27 or higher (a measure of body weight relative to height)
- People who have been diagnosed with joint pain or stiffness caused by aromatase inhibitor treatment (known as AIMSS)
- People whose Omega-3 Index blood level is below 8% (a measure of omega-3 fatty acids in the blood) (confirm with trial site)
- People who have had an average joint pain score of 4 or higher on a standard pain questionnaire called the Brief Pain Inventory, measured within the 7 days before joining the trial
- People who are willing and able to follow the study requirements and have provided written consent to participate
Who may not be able to join:
- People who are currently taking blood-thinning medications, such as Warfarin, Lovenox, Eliquis, or Xarelto, among others
- People who have an allergy to cherries, fish, or fish products
- People who have ever been diagnosed with rheumatoid arthritis or other inflammatory joint conditions, such as reactive arthritis, ankylosing spondylitis, or psoriatic arthritis
- People whose diabetes is not well controlled, as determined by their treating doctor, whether or not they use diabetes medications or insulin
- People who have ever had a stroke or a temporary stroke-like episode (sometimes called a mini-stroke or TIA)
- People who have started taking a new pain-relief medication, or had a dose change to an existing one, in the 14 days before joining — this includes opioids, anti-inflammatories, paracetamol, and certain antidepressants or nerve pain medications, among others
- People who have used steroid medications by mouth or by injection into a joint in the 30 days before joining, such as prednisone, dexamethasone, or similar medications
- People who have had a fracture or surgery in the affected joint within the past 6 months
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Philip Chang, DO, Cedars-Sinai Medical Center
Phone: 3104232133
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The primary objective is to assess changes in joint function between groups.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.